Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

May 30, 2015 10:00 AM ET


Company Overview of Peptimmune, Inc.

Company Overview

Peptimmune, Inc. went Out of Business. Peptimmune, Inc., a clinical stage biotechnology company, develops peptide and peptide-copolymer therapeutics for the treatment of CNS and autoimmune disorders. It provides PI-2301 peptide copolymer for the treatment of multiple sclerosis; and DEEP (Directed Expansion of Epitope Permutations) vaccines for viral, bacterial, and parasitic infectious diseases. Peptimmune, Inc. was founded in 2002 and is based in Cambridge, Massachusetts.

64 Sidney Street

Suite 380

Cambridge, MA 02139

United States

Founded in 2002





Key Executives for Peptimmune, Inc.

Peptimmune, Inc. does not have any Key Executives recorded.

Similar Private Companies By Industry

Company Name Region
Advanced Life Sciences, Inc. United States
Major Pharmaceuticals, Inc. United States
Biofilm, Inc. United States
St. Jon Laboratories Inc. United States
Unigen Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Peptimmune, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at